12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Rituxan rituximab: Phase III data; marketed to treat low-grade NHL

Interim data from 328 previously untreated patients with aggressive NHL in IDPH's 400-patient Phase III trial showed a 1-year survival rate of 83 percent with Rituxan plus chemotherapy compared to 68 percent with chemotherapy alone....

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >